依达拉奉联合东菱迪芙治疗急性脑梗死疗效观察

Efficacy observation of Edaravone combined with Batroxobin in the treatment of acute cerebral infarction

目的探讨依达拉奉联合东菱迪芙治疗急性脑梗死的疗效。方法将90例急性脑梗死患者随机分为三组:单用依达拉奉治疗组30例,单用东菱迪芙治疗组30例,依达拉奉联合东菱迪芙治疗组30例。比较三组患者的临床疗效、治疗前后神经功能缺损程度评分以及血纤维蛋白原水平的变化。结果依达拉奉联合东菱迪芙治疗组的显效率(83.3%)明显高于单用依达拉奉治疗组(53.3%)和单用东菱迪芙治疗组(50.0%),差异有统计学意义(P<0.05)。治疗后三组的神经功能缺损程度评分及血纤维蛋白原水平均显著低于治疗前(P均<0.01);但联合用药组神经功能缺损程度评分及血纤维蛋白原水平均低于其他两组,差异有统计学意义(P<0.01)。结论依达拉奉联合东菱迪芙治疗急性脑梗死患者的疗效优于单用依达拉奉或单用东菱迪芙治疗。

Objective To explore the efficacy of Edaravone combined with Batroxobin in the treatment of acute cerebral infarction.Methods 90 patients with acute cerebral infarction were randomly divided into three groups：Batroxobin group 30 patients,Edaravone group of 30 patients,combination of Batroxobin and Edaravone treatment group 30 patients.The clinical efficacy,neurological deficit scores and changes of fibrinogen levels were compared before and after treatment.Results The effective rate of combination group was 83.3%,significantly higher than Edaravone group（53.3%） and Batroxobin group（50.0%）（P〈0.05）.Neurological deficit scores and fibrinogen levels reduced after treatment（P〈0.01） in both group.Fibrinogen levels of combination group was significantly lower than that of the other two groups（P〈0.01）.Conclusion In the treatment of acute cerebral infarction,the efficacy of Edaravone combined with Batroxobin was better than single use of edaravone or Batroxobin.